Hsbc Holdings PLC Decreases Stock Position in GE HealthCare Technologies Inc. $GEHC

Hsbc Holdings PLC trimmed its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 2.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 898,798 shares of the company’s stock after selling 18,137 shares during the period. Hsbc Holdings PLC’s holdings in GE HealthCare Technologies were worth $73,920,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of GE HealthCare Technologies during the fourth quarter valued at about $596,024,000. Barrow Hanley Mewhinney & Strauss LLC acquired a new position in shares of GE HealthCare Technologies in the fourth quarter worth about $533,655,000. Capital Research Global Investors boosted its holdings in GE HealthCare Technologies by 25.0% in the third quarter. Capital Research Global Investors now owns 24,972,556 shares of the company’s stock valued at $1,875,400,000 after purchasing an additional 4,998,154 shares during the last quarter. Cynosure Group LLC boosted its holdings in GE HealthCare Technologies by 21,045.4% in the fourth quarter. Cynosure Group LLC now owns 4,365,462 shares of the company’s stock valued at $358,055,000 after purchasing an additional 4,344,817 shares during the last quarter. Finally, Dodge & Cox grew its stake in GE HealthCare Technologies by 16.8% during the 3rd quarter. Dodge & Cox now owns 27,517,311 shares of the company’s stock valued at $2,066,550,000 after purchasing an additional 3,949,361 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Price Performance

Shares of GEHC opened at $60.64 on Tuesday. GE HealthCare Technologies Inc. has a 52 week low of $58.75 and a 52 week high of $89.77. The company has a current ratio of 1.22, a quick ratio of 0.95 and a debt-to-equity ratio of 0.95. The firm has a market cap of $27.58 billion, a price-to-earnings ratio of 14.51, a PEG ratio of 1.68 and a beta of 0.74. The stock has a 50 day moving average of $65.23 and a 200-day moving average of $74.42.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by ($0.08). The firm had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.04 billion. GE HealthCare Technologies had a net margin of 9.10% and a return on equity of 20.46%. The business’s revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.01 earnings per share. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. As a group, analysts forecast that GE HealthCare Technologies Inc. will post 4.89 EPS for the current year.

Analyst Upgrades and Downgrades

GEHC has been the topic of a number of recent analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $85.00 target price on shares of GE HealthCare Technologies in a research report on Thursday, April 30th. Argus dropped their price target on shares of GE HealthCare Technologies from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Jefferies Financial Group cut their price target on shares of GE HealthCare Technologies from $105.00 to $90.00 in a report on Thursday, April 30th. Wells Fargo & Company reduced their price objective on shares of GE HealthCare Technologies from $97.00 to $75.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Finally, Barclays decreased their price objective on shares of GE HealthCare Technologies from $87.00 to $78.00 and set an “equal weight” rating for the company in a report on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $80.21.

Insider Activity at GE HealthCare Technologies

In other GE HealthCare Technologies news, Director Kevin Lobo bought 10,000 shares of the company’s stock in a transaction on Friday, May 22nd. The shares were bought at an average cost of $64.18 per share, with a total value of $641,800.00. Following the completion of the acquisition, the director owned 14,363 shares of the company’s stock, valued at approximately $921,817.34. This trade represents a 229.20% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Peter J. Arduini purchased 4,169 shares of GE HealthCare Technologies stock in a transaction dated Thursday, April 30th. The stock was acquired at an average price of $59.92 per share, for a total transaction of $249,806.48. Following the completion of the transaction, the chief executive officer owned 259,424 shares in the company, valued at approximately $15,544,686.08. The trade was a 1.63% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 21,847 shares of company stock valued at $1,361,355 in the last ninety days. 0.36% of the stock is owned by insiders.

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.